Biogen Idec Inc. (BIIB)

Index: Nasdaq 100
-0.09%
-$0.25
$280.32
23:26 23/06/17
$280.32
23:26 23/06/17
DAILY VARIATION
-0.09%
-$0.25
VOLUME
2,197,084
DATA
52 Week High
n/a
52 Week Low
n/a
Shares Issued
212.12m
Market Cap
$59,460.14m
RiskGrade
n/a
Beta
n/a
MENU

Biogen Idec Inc. Overview

In November 2003, Biogen and IDEC Pharmaceuticals finalised their $6bn merger, creating Biogen Idec, the third-largest biotechnology company in the world. The company is now a global leader in the development, manufacturing, and commercialisation of novel therapies. Its major products include treatments for relapsing multiple sclerosis, certain B-cell non-Hodgkin's lymphomas and adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Intraday Chart

Historic Charts

Latest F'cast
Div Yield n/a 0.0%
Div Cover n/a n/a
Op Mrgn n/a 44.7%
ROCE n/a
Latest F'cast
P/E n/a 1,223.5
PEG n/a 9.2
Pr/Revenue n/a 5.2
Pr/Book n/a
Latest F'cast
Revenue 40.0% -3.7%
PBT 59.1% n/a
EPS 58.0% 2.3%
DPS n/a 0.0%

Key Fundamentals

slide to see more
Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
2012-12-31 5,516.46 1,859.62 580.00¢ 25.2 1.8 14% n/a 0.0%
2013-12-31 6,932.20 2,480.58 786.00¢ 35.6 1.0 36% n/a 0.0%
2014-12-31 9,703.32 3,946.63 1,242.00¢ 27.3 0.5 58% n/a 0.0%

Forecast

slide to see more
Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
2016-12-31 11,448.80 5,831.64 2,022.00c 1,245.0 19.8 63% 0.00c 0.0%
2017-12-31 11,376.95 5,085.46 2,052.15c 1,223.5 820.5 1% 0.00c 0.0%
2018-12-31 12,011.00 6,007.17 2,255.07c 1,125.3 113.8 10% 0.00c 0.0%

Regulatory News

No results found

Newspaper Links

No results found